Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 4 1Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Neutropenia 1Neoplasms 1Fever 1Exanthema 1Colorectal Neoplasms 1

Interventions

Fluorouracil 131Leucovorin 127Oxaliplatin 93Bevacizumab 86Irinotecan 74Capecitabine 63Cetuximab 47Folfox protocol 32Panitumumab 18regorafenib 16trifluridine tipiracil drug combination 15Drug Therapy 14Chemotherapy, Adjuvant 13IFL protocol 10Floxuridine 10Radiotherapy 9Tegafur 7Neoadjuvant Therapy 7Levoleucovorin 7Laparoscopy 7Aspirin 7pembrolizumab 6atezolizumab 6Trifluridine 6Celecoxib 6XELOX 5Mitomycin 5Colonoscopy 5tipiracil 4sintilimab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Colorectal Neoplasms × Anti-Bacterial Agents × Clear all
NCT01931150 2017-01-13

Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT

Memorial Sloan Kettering Cancer Center

Phase 3 Completed
11 enrolled 7 charts
Gastrointestinal

Exanthema, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡